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Summary 
Interactions between endothelium and vascular  smooth muscle cells play a major role in the 
biology of the blood vessel wall. Growth factors released from endothelial cells control in part 
the normal and pathological proliferation of vascular smooth muscle cells. Endothelial deposits 
of C5b-9 proteins, the membrane attack complex of complement (MAC), have been found in 
a variety of pathological tissues in which cell proliferation is an early characteristic abnormality, 
including atherosclerosis. We have explored a possible bridging role for terminal complement 
C5b-9 proteins in eliciting focal signals  for cell proliferation by releasing growth factors from 
endothelial cells. We found that both bovine aortic and human umbilical vein cells respond to 
the MAC by releasing basic fibroblast growth factor and platelet-derived growth factor. These 
mitogens stimulate DNA synthesis in Swiss 3T3, vascular smooth muscle, and glomerular mesangial 
cells. Based on these findings, we propose that complement-induced release of mitogens from 
endothelial cells is a novel pathogenic mechanism for proliferative disorders. 
I 
n addition to its cytolytic properties, the membrane attack 
complex of complement (MAC) 1 is now recognized as a 
mediator of a range of cellular processes  in the absence  of 
cell death (for a review see reference 1). Recent work from 
our laboratory suggested that focal initiation of cell prolifer- 
ation may be a new pathobiological function of the comple- 
ment system (2). The endothelium represents a particularly 
relevant model to further extend these findings. On the one 
hand, endothelial cells, located at the interface between blood 
and tissues,  are natural targets of activated complement. On 
the other hand,  endothelial cells  synthesize several potent 
mitogens, such as basic fibroblast growth factor (bFGF) and 
platelet-derived growth factor (PDGF),  which are released 
in response to stimuli not yet completely understood (for a 
review see reference 3). Using an in vitro method of gener- 
ating C5-9 complexes from purified complement components, 
we were able to study mitogenic activity generated by en- 
dothelial cells without the confounding influence of mere- 
1 Abbreviations used in this paper: BAEC, bovine aortic  endothelial  cell; 
bFGF,  basic  fibroblast  growth  factor;  [Ca2+]i, intracellular  calcium; 
HUVEC, human umbilical  vein endothelial cell; MAC, membrane attack 
complex of complement; PDGF, platelet-derived growth factor; RASM, 
rat  aortic smooth muscle cell. 
brane-bound antibody, complement fragments C3a and CSa, 
and/or exogenously added mitogens. We report here that in 
two types of endothelial cells, one derived from bovine aortas 
and the other from human umbilical veins, C5b-9 proteins 
provide a potent stimulus for the release of two polypeptide 
mitogens synthesized by these cells, bFGF and PDGF. 
Materials and Methods 
Cell Culture.  Bovine  aortic endothelial cells (BAEC-65), human 
umbilical vein endothelial cells (I-IUVEC), and rat aortic smooth 
muscle cells (RASM) were kindly provided by Dr. M. A. Gim- 
brone, Jr. (Brigham and Women's Hospital). Swiss 3T3 cells were 
kindly supplied by Dr. H. Green (Harvard Medical School). Pat 
mesangial cells (ILMC) were kindly provided by Dr. J. Bonventre 
(Massachusetts General Hospital, Boston, MA). 
BAEC-65 were seeded  in 35-ram dishes and grown to confluence 
in DME supplemented with 10% bovine calf serum (37~  95% 
air/5%  CO2). Swiss 3T3  cells used for mitogenic assays were 
plated in 96-multiwell plastic culture plates and grown to confluence 
in DME-10% bovine calf serum. 24 h after reaching confluence, 
the cells were made quiescent by incubation for 24 h in DME-0.5% 
calf serum. HUVEC were cultured in 199/HBSS containing 20 
mM  NaCO3,  20  mM  Hepes, 2  mM L-glutamine, 20%  heat- 
inactivated FCS, 50/~g/ml endothelial cell growth factor (ECGF) 
(Biomedical Technologies, Inc., Stoughton, MA), and 100/~g/ml 
heparin (Sigma Chemical Co., St. Louis, MO). 
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calf serum, and RMC in RPMI supplemented with 15%  FCS 
(37~  95% air/5% CO2). For mitogenic assays, the cells were 
plated in 96-multiwell plates, made quiescent, and assayed  exactly 
as described above for 3T3 cells. 
MAC Formation on Endothelial Cells and Assay.for Mitogenic Ac- 
tivity  in the Conditioned Media.  Complement protein C5b6 was 
made from purified C5 and C6, using factor B, cobra venom factor 
(CVF) (all purchased from Quidell, San Diego, CA), and recom- 
binant factor D (gift of T. White, Metabolic Biosystems, Moun- 
tain View, CA)  (4). Ni + (1.0 raM)  was used to  stabilize the 
CVFBb convertase (5). The C5b6 was fractionated by HPLC on 
a DEAE column (AP-1 Protein Pak 8HR.; Waters, Milford, MA), 
as described (2). One unit of C5b6 was defined as the amount of 
C5b6 required to produce 50%  lysis of 5  x  107 human  RBC 
when incubated in a total volume of 300/~1 with C7 (0.1 #g), 
C8 (0.5/zg), and C9 (0.5/zg) (2). 
To form the MAC on endothelial ceUs, purified human terminal 
complement components diluted in DME were added sequentially 
as follows:  400/,tl of C5b6 containing x number of  hemolytic units, 
400/zl of C7 (30/zg/ml),  and 3 rain later, 400/~1 of C8 plus C9 
(30 ~g/ml each) (C7, C8, and C9 were from Quidell). After 45 
min, the culture medium was removed, spun down (1,300 g at 4  ~ 
for 5 rain), and then added to indicator cells to test for mitogenic 
activity. 
Mitogenic Assays.  Mitogenic activity was detected by adding 
dilutions of the conditioned media to indicator cells, and measuring 
[3Hlthymidine incorporation into DNA, as described (2). 
Neutralization of Mitogenic Activity with Specific Antibodies.  Con- 
ditioned medium from MAC-treated BAEC and HUVEC were col- 
lected after 45 min and incubated with neutralizing antibodies: 
100 #g/ml goat anti-human PDGF (Upstate Biotechnology Inc., 
Lake Placid, NY), and 50/zg/ml rabbit anti-recombinant human 
bFGF (kindly provided by Dr. E D'Amore, Children's Hospital, 
Boston, MA). The antigen antibody complexes were immunopre- 
cipitated  by incubation with protein G-Sepharose (60/.tg/ml, Sigma 
Chemical Co.), followed by centrifugation.  To control for non- 
specific effects of the antibodies, an irrelevant goat and rabbit anti- 
body was used. Cross-reactivity  between anti-PDGF and anti-bFGF 
was ruled out by analyzing the effect of anti-bFGF on PDGF and 
of anti-PDGF on bFGF-stimulated 3T3 cells. 
bFGF ELISA.  A commercially available solid phase ELISA 
specific for human bFGF and that cross-reacts 100% with bovine 
bFGF was performed according to the manufacturer's instructions 
(R&D  Systems, Minneapolis, MN).  The ELISA uses a mouse 
anti-human bFGF monoclonal antibody, and a rabbit polyclonal 
anti-bFGF antibody conjugated to horseradish peroxidase. Dilu- 
tions of recombinant human bFGF were used for the standard cali- 
bration curve. 
Measurement of lntracellular Ca 2+ Activity ([Ca2+]i).  Endothelial 
cells were plated at a density of 6  x  103 cells/cm  2 on 12-mm glass 
coverslips that had been placed in the wells of 24-well sterile cul- 
ture plates. The cells were grown to confluence, and on the day 
of the experiment, loaded  for 30 rain at 37~  with 5/xM fura-2-AM 
dissolved in DMSO-20% pluronic acid, and washed and placed in 
serum-free DME medium. The coverslips were placed in a water- 
jacketed chamber on a light-shielded, heated stage of an inverted 
fluorescence  microscope (37 ,+ 0.5~  Fluorescence  measurements 
were performed  in a dual excitation  spectrofluorimeter  (model CM2; 
SPEX Industries, Edison, NJ) (6). The excitation  wavelengths  were 
340 and 380  -+  1.8 nm. A dichroic mirror deflected the excited 
light (400 nm cut-off) to the perfusion chamber on the stage of 
an inverted  epifluorescence  microscope  (Nikon, Nikon, Japan). The 
fura-2 emission signals were collected for each wavelength at 500 
_+  5 nm. [Ca2+]i was determined by the equation: [Ca2+]i = Kd 
x  (R  -  Rmin)/(Rm~  -  R)(7). 
Results 
Detection  of Mitogenic Activity  in Conditioned Medium from 
BAEC  and HUVEC.  To  investigate whether  the  MAC 
would induce the release of mitogens from endothelial cells, 
BAEC were sequentially exposed to human purified comple- 
ment components to form the MAC. First, the cells were 
incubated in serum-free medium containing purified C5b6 
protein and C7 for 3 min. C8 and C9 were then added to 
form the MAC. After 45 min, the culture medium was re- 
moved, spun down, and the supernatant added to indicator 
quiescent  Swiss  3T3  cells  to  measure DNA  synthesis by 
[3H]thymidine incorporation.  As  shown in Fig.  1 a,  me- 
dium conditioned by MAC-treated BAEC stimulated DNA 
synthesis severalfold, indicating that a potent mitogenic ac- 
tivity was released from the endothelial cells in response  to 
the MAC. 
Release of mitogenic activity by MAC-treated endothelial 
cells was rapid, achieving maximal levels within 10 min after 
exposure to the MAC. Furthermore, replacement of the con- 
ditioned medium every 10 min for 2 h  after formation of 
the MAC, failed to detect any sustained release of mitogens 
after the initial 10 min. During the first  2 h  after release, 
the activity was not degraded by endothelial cells, since no 
difference was detected in the mitogenic activity harvested 
from cultures 10, 20,  and 60 min, and 2 h after exposure 
to the MAC. 
Activation of complement is highly regulated. Endothelial 
cells, like most mammalian cells, have two well-characterized 
membrane-bound proteins, decay accelerating  factor (DAF) 
and CD59, that restrict complement activation at the plasma 
membrane (8). Regulation by DAF and CD59 at the C3 and 
C8/C9 steps, respectively, is "species restricted;' meaning that 
DAF and CD59 are most effective at inhibiting homologous 
complement and less effective in heterologous systems like 
the bovine cells/human complement used in the experiments 
described  thus far. To further assess the potential relevance 
in human diseases of the phenomenon of MAC-induced re- 
lease of mitogens from endothelial cells, experiments were 
repeated using a homologous system composed of HUVEC 
and human complement. The results show that a potent mito- 
genic activity is also released by the MAC from HUVEC 
(Fig.  1 b). 
The ability of the MAC to release mitogenic activity from 
endothelial cells was dose dependent: increasing the concen- 
tration of C5b6, which is limiting in MAC formation, in- 
creased the mitogenic activity of the cell supernatant (Fig. 
2 a). In BAEC, four functional units of C5b6 released mito- 
genic activity equivalent to =80%  of the activity obtained 
with 10%  calf serum, used as positive control. The mito- 
genic response of the indicator 3T3 cells to the conditioned 
medium was also dose dependent, varying with the concen- 
tration of cell supernatant used (Fig.  2 b). 
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C7  C8  Figure  1.  Mitogenic  activity  in  conditioned 
medium from MAC-treated BAEC and HUVEC 
cells. Either BAEC (a) or HUVEC (b) cultured 
in 35-mm dishes were washed three times to re- 
move residual serum and growth factors and then 
exposed to the MAC formed with 4 U  of C5b6, 
as described  in Materials and Methods. After 45 
min, the conditioned media were removed and ap- 
plied to quiescent 3T3 cells. 3T3 cells were used 
as indicators of mitogenic activity, assessed by the 
uptake of [3H]thymidine. As control for sponta- 
neous release of mitogens, endothelial cells were 
maintained for 45 rain in DME medium without 
any complement components (COND MEDIUM). 
DME 10% serum served as a positive control. Each 
point is the mean •  SEM of quadruplicate values 
obtained in a representative experiment. (Inset) Re- 
lease of growth factors  from BAEC occurs  only 
in response  to combinations of terminal comple- 
ment components that form the MAC. BAEC were 
exposed to terminal complement components ei- 
ther isolated or in different combinations. 45 min 
later,  the  media were  removed and assayed for 
mitogenic  activity  in  the  indicator  3T3  cells. 
(C5b678-9 Prior) Results of mixing all terminal 
complement components 5 min before addition to 
the endothelial cells. 
Both bFGF and PDGF Contribute to the Mitogenic Activity 
Released by the MAC from BAEC and HUVEC.  Both bFGF 
and PDGF are known potent mitogens for the 3T3 cells used 
in our mitogenic assays. It is known that bFGF, but not PDGF, 
is heat sensitive and has a high affinity for heparin, thus ad- 
sorbing  tightly to heparin-Sepharose  resins (9). Heat (56 ~ 
for 10 min), or exposure to heparin-Sepharose,  reduced the 
mitogenic activity released by the MAC from BAEC by 30 
to 40% (data not shown), indicating the possible contribu- 
tion of bFGF. This was confirmed by direct quantification 
ofbFGF using an ELISA specific  for human bFGF. This assay 
detected an increased concentration of bFGF in the condi- 
tioned media of MAC-treated HUVEC as compared with 
control cells. The amount of bFGF in the conditioned media 
was proportional to the mitogenic activity of the media and 
dependent on the concentration of C5b6 used to form the 
MAC (Table 1). 
To further elucidate the nature and relative contribution 
of the mitogens released from endothelial cells in response 
to the MAC, we used specific neutralizing anti-bFGF  and 
anti-PDGF antibodies, insolubilized with protein G coupled 
to Sepharose beads. The mitogenic activity released by the 
MAC from both BAEC and HUVEC was blocked =60% 
by anti-PDGF and =30-40% by anti-bFGF. Moreover, the 
mitogenic activity was completely blocked when the condi- 
tioned media were sequentially exposed to both neutralizing 
antibodies (Fig. 3, a and b, respectively). The blocking effect 
was not due to nonspecific effects of the antibodies, or the 
protein G-Sepharose immune-immobilization  procedure be- 
cause no neutralizing effect was detected with irrelevant spe- 
cies, class- and type-matched antibodies  (Fig. 3). 
Mechanism of MAC-induced Release of Mitogens from En- 
dothelial Cells.  The conditioned media from BAEC  and 
HUVEC expressed high mitogenic activity only when the 
cells were exposed to all terminal components sequentially 
in a manner that leads to formation of the MAC (Fig. 1, 
inset). Increased mitogenic activity was not observed when 
cells were incubated with (a) each terminal complement com- 
ponent alone; (b)C5b6  +  C7; (c)C5b6  +  C7  +  C8; (d) 
any other combination of the complement components that 
does not result in formation of the MAC; or (e) a mixture 
derived from the sequential addition of C5b6  +  C7  +  C8 
+  C9 incubated together for 5 rain before contact with the 
endothelial cells (C5b678-9 Prior, Fig. I inset). Under the latter 
conditions,  the short half-life of the C566-7 complex in the 
fluid phase precludes effective  MAC insertion into the plasma 
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Figure 2.  The MAC-induced  release of mitogens from BAEC is dose 
dependent. (a) BAEC release  more mitogens  as the concentration  of C5b6 
used to form the MAC is increased. (b) Medium  conditioned  by MAC- 
treated  BAEC  induces  dose-dependent  synthesis  of  DNA in 3T3 cells. BAEC 
were exposed to the MAC (4 U of C5b6), and the indicator 3T3 cells 
were stimulated  with decreasing concentrations  of the cell supernatant. 
membrane. Thus, the release of mitogens from endothelial 
cells seems to require assembly of the MAC in the cell mem- 
brane. 
Insertion of the MAC into the plasma cell membrane in- 
creases the leak of Ca  2+ from the extracellular medium and 
transiently increases  [Ca2+]i (10-12).  To further investigate 
whether insertion of the MAC into the plasma membrane 
of the endothelial cell is a necessary condition for growth 
factor release, we determined in parallel the effect of different 
concentrations  of  the  MAC  on  the  cytosolic-free Ca  > 
[CF +  ]i of fura-2-1oaded endothelial cells and on the release 
of mitogens from those cells. The results of these experiments 
showed that mitogens were released into the media only at 
MAC concentrations that induced effective MAC insertion 
into the membrane as revealed by a transiently increased cyto- 
solic  [Ca2+]i,  a  marker  of MAC-pore  formation  in  the 
plasma membrane (Fig. 4). Furthermore, the mitogenic ac- 
tivity released by the MAC was proportional to the increased 
[Ca2+]i,  as  shown in Fig.  4. 
Since insertion of MAC pores into the plasma membrane 
can lead to colloid-osmotic cell lysis of the target cells, we 
Table  1.  Presence  of bFGF in Conditioned  Media of MAC-treated 
HUVEC 
Source  of 
conditioned media  C5b6  bFGP 
(u)  pg/ml 
Untreated  cells  -  13 
CSb67-treated cells  4  13 
C5b6789-treated cells (MAC)  2  27 
4  41 
A quantitative  ELISA  specific  for human  bFGF was used to measure  the 
concentration of bFGF in the conditioned  media of control and MAC- 
treated cells. 
investigated the relationship between MAC-induced cytol- 
ysis and the release of mitogenic activity by MAC-treated 
endothelial cells. Cell viability and lysis were assessed by the 
release of 5~Cr, and the uptake of trypan blue into the cells. 
Exposure of the cells to the MAC at concentrations resulting 
in significant release of mitogenic activity did not affect ei- 
ther the release of 51Cr or the uptake of trypan blue.  Fur- 
thermore, follow-up of the endothelial cells for up to 48 h 
after treatment with the MAC failed to detect any significant 
morphologic differences when compared with control cells. 
The results of these experiments indicate that release of mito- 
genic activity from endothelial cells is a sublytic effect of the 
MAC. 
In response to the MAC, nucleated cells shed membrane 
vesicles that are enriched in MAC proteins, a mechanism that 
contributes to limit the life span of the MAC pore and to 
restrict colloidosmotic lysis (1,  13). To investigate whether 
mitogens could be released from the MAC entrapped in mem- 
brane vesicles shed in response to the MAC, conditioned media 
from MAC-treated endothelial cells were assayed for mito- 
genic activity before and after ultracentrifugation at 25,000 
g. Others have shown that these conditions are sufficient to 
bring down the membrane vesicles (13). No difference in the 
mitogenic activity was detected when the conditioned media 
were assayed before and after ultracentrifugation, indicating 
that the growth factors released apparently were neither en- 
trapped inside membrane vesicles nor attached to their mem- 
branes. 
bFGF  binds  with  low  affinity to  heparan  sulfate  pro- 
teoglycans on the cell surface and extracellular matrix (14). 
Proteoglycan binding appears to protect bFGF from degra- 
dation and provides  a reservoir  of active bFGF.  Release of 
bFGF from cell surface and extracellular matrix occurs  by 
(a) proteolysis of the proteoglycan core protein; (b) partial 
degradation of the heparan sulfate component with heparinase; 
and (c) treatment with heparin, which binds bFGF with high 
affinity, and competes strongly with the low affinity  extracel- 
lular binding site for bFGE Incubation of cultured endothelial 
cells with heparin removes active bFGF from the cell-associated 
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Figure  3.  bFGF  and PDGF are released by the MAC 
from both BAEC and HUVEC. Endothelial cells were 
exposed to the MAC as in Fig. 1. Conditioned medium 
from MAC-treated BAEC (a) and HUVEC (b) were 
collected after 45 min, incubated with neutralizing an- 
tibodies, and the antigen antibody complexes were im- 
munoprecipitated,  as  described  in  Materials  and 
Methods.  Exposure of a conditioned medium to both 
antibodies was done sequentially, i.e., the medium was 
first incubated with anti-bFGF and immunoprecipi- 
tared, and then the procedure was repeated with anti- 
PDGE  Controls  with  irrelevant  class- and  type- 
matched irrelevant antibodies were performed exactly 
as with specific neutralizing  antibodies.  (*) The bar 
represents the results obtained testing either rabbit or 
goat  irrelevant antibodies. 
nM 
5(~1 i  XOs~ec 
ICo++~. 
100  ~.~  ~ 
0  O.L 
100 
75 
~  50 
~,. 
~  ~25 
~  ~ 
[).5  I  2  4 
C566  (Units) 
0  O. I  0.5  1  2  4  C5(r (Units) 
Effect of increasing concentrations  of the MAC on cytosolic  Figure  4. 
free-calcium concentration  and release of mitogens from HUVEC. (%p) 
BAEC cultured  in gelatin-coated  glass coverslips were loaded  with fura 
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extracellular  sites partially  depleting the cell surface and ex- 
tracellular matrix reservoirs (15). To differentiate whether the 
MAC releases mitogens from intracellular  pools or from the 
extracellular  binding sites,  BAEC were incubated for 5 min 
at 37~  and washed three times with DME medium con- 
taining  100/~g/ml  heparin,  before exposure to  the MAC. 
No difference  in mitogenic  activity was detected in media 
conditioned by BAEC pretreated and untreated with heparin. 
These results indicate that under our experimental  conditions, 
the MAC is releasing bFGF predominantly from an intracel- 
lular  source. 
Mitogens Released by the MAC from Endothelial Cells Stimu- 
late Proliferation  of Vascular  Smooth Muscle Cells.  Growth factors 
released from endothelial ceils play  a major role in the bi- 
ology of the vascular wall by controlling the normal and patho- 
logical proliferation of vascular smooth muscle cells.  To de- 
2-AM (5/IM) for 30 min, washed with DME, and placed in the perfusion 
chamber of an inverted epifluorescence microscope.  Different  concentra- 
tions of C5b6 and 9/~g/ml C7 were added 3 min before addition  of 9 
/xg/ml C8 +  C9 (arrows). Fluorescent measurements were performed using 
a SPEX CM2 dual-excitation  spectrofluorimeter,  as described in Materials 
and Methods.  (Bottom)  Mitogenic activity induced in indicator 3T3 cells 
by conditioned media from BAEC cells exposed  to the same concentra- 
tions of C5b6,  C7,  and C8  +  C9 used  above in the [Ca2+]i  measure- 
ments.  Other experimental  conditions  were exactly  as in Fig.  1. Table  2.  Conditioned Medium from MAC-treated BAEC 
Stimulates DNA  Synthesis in RASM and Rat Glomerular 
Mesangial Cells 
[3H]Thymidine uptake 
Cell type  Control 
vation may represent a lower sensitivity to the MAC in the 
human cells due to the more efficient action ofCD59, a com- 
plement regulatory protein that limits formation of the MAC 
in a species-specific manner; e.g., C5b-9 is more effectively 
limited by human than by heterologous CD59. It could also 
reflect  different amounts  and/or  specific  activities  of the 
MAC (4 U)  mitogens released from either cell type. We have previously 
shown that the MAC can deliver mitogenic signals directly 
cpm/weH  to 3T3 cells (2). However, the mitogenic activity present in 
1,800  _+ 79  the supernatants of MAC-treated endothelial cells is not due 
2,800  _+ 86  to MAC complexes carried over from the endothelial cells 
media onto the 3T3 cells because (a) the mitogenic activity 
can be completely blocked with anti-bFGF and anti-PDGF 
antibodies (Fig. 3); and (b) the mitogenic activity present in 
the supernatants of MAC-treated endothelial cells could be 
preserved for several days at 4~  and for at least 2 wk by 
freezing the samples;  given the very short half-life of the 
C5b6-7 complex in fluid phase (seconds), it is extremely un- 
likely that any MAC insertion could occur after those time 
intervals. In conclusion, a direct mitogenic effect of the MAC 
is not responsible for the mitogenic activity present in con- 
ditioned media of MAC-treated endothelial cells. 
Both PDGF and bFGF synthesized by endothelial cells are 
potent mitogens for mesenchymal cells. PDGF is secreted in 
response to thrombin, cell injury, and other stimuli (19). bFGF, 
in contrast, is a cell-associated  mitogen that lacks a signal 
peptide characteristic of proteins secreted via the exocytotic 
pathway (20, 21). This nonglycosylated growth factor is stored 
in a soluble active form in the cell cytoplasm and also is at- 
tached to the cell surface via glycosyl-phosphatidylinositol 
(GPI) residues (22).  No stimulus for bFGF release has been 
characterized, and it is believed that it is liberated through 
breaks in the plasma membrane when cells are mechanically 
damaged (23). The results of the experiments presented here 
indicate that insertion of the MAC into the plasma mem- 
brane and a MAC-induced membrane lesion are a necessary 
condition for the release of growth factors (Fig. 4). This le- 
sion, however, must be transient and very short-lived since 
the release of growth factors occurs in the absence of any 
detectable cell lysis or compromise of the cell viability for 
at least 48 h. The nonlethal transient changes in membrane 
permeability produced by the MAC (24, 25) that we and others 
have previously documented, may support different, not neces- 
sarily exclusive, mechanisms for release of PDGF and bFGF: 
(a) the cells may undergo a very rapid and transient swelling 
that may open permeability pathways for the release of soluble 
cytoplasmic compounds; (b) the MAC-induced ionic changes, 
including the transient increase in intracellular Ca  z+,  may 
activate the exocytic pathways; and (c) mitogens may leave 
the cell through the MAC pore itself. In addition, signal trans- 
duction through CD59 could also contribute to the release 
of growth  factors from  endothelial  cells.  CD59,  a  GPI- 
anchored complement regulatory protein complexed to pro- 
tein tyrosine kinases,  has been shown to activate metabolic 
pathways in other cell types (26).  The possibility that the 
MAC-induced release of mitogens observed in our experi- 
ments could require increased expression of mRNA and/or 
protein synthesis is unlikely because maximum release oc- 
Terminal C Proteins C5b-9 Release bFGF and PDGF from Endothelial Cells 
Aortic  smooth muscle 
Glomerular mesangial 
820  _+  50 
780  _+ 48 
Cells were grown to confluence,  made quiescent, and exposed to condi- 
tioned media from BAEC cells that were and were not treated with the 
MAC. [3H]Thymidine  uptake was assessed  36 h later as shown in Fig. 1. 
termine  whether  vascular  smooth  muscle  cells  are  also 
stimulated by the growth factors released in response to the 
MAC, we stimulated quiescent RASM cells with conditioned 
media from MAC-treated BAEC.  The results indicate that 
a strong mitogenic response was elicited in quiescent RASM 
cells when they were stimulated with the conditioned media 
form MAC-treated endothelial cells  (Table 2). 
Mitogens Released by the MAC from Endothelial Cells Stimu- 
late Proliferation of  Rat Glomerular Mesangial Cells.  Deposition 
of the MAC and mesangial cell proliferation is a frequent 
finding in various proliferative glomerular diseases in humans 
(16, 17), and both bFGF and PDGF have been shown to be 
mitogenic for glomerular mesangial cells. When quiescent 
RMC were incubated with conditioned media from MAC- 
treated BAEC, their proliferation rate, assessed by incorpora- 
tion of [3H]thymidine, increased four- to fivefold (Table 2). 
Discussion 
We have documented that interaction of the MAC with 
endothelial cell membranes results in the release of both bFGF 
and PDGF,  two well-characterized growth factors synthe- 
sized by these cells. Conclusive evidence for the major con- 
tribution of these two growth factors to the mitogenic activity 
present in media conditioned by MAC-treated endothelial cdls 
was provided by complete blockade of the mitogenic activity 
by the sequential addition of neutralizing anti-bFGF and anti- 
PDGF antibodies (Fig.  3).  The presence of bFGF was fur- 
ther confirmed by the direct ELISA measurement of bFGF 
(Table 1). Which isoforms of PDGF are released in response 
to the MAC, and whether other growth regulatory mole- 
cules synthesized by endothelial cells (18) are also released 
in small amounts together with  PDGF  and bFGF,  is not 
known at present and is under investigation. 
Formation of the MAC with the same concentrations of 
all terminal complement components, released a more po- 
tent mitogenic activity from BAEC than from HUVEC (Fig. 
1).  Since the number of cells in a confluent monolayer of 
BAEC  and  HUVEC  (8.5  10 5  +  10  4 and  10 6  +  1.8  10 4, 
respectively) does not account for this difference, the obser- 
990 curred as early as 10 min after exposure of the cells to the 
MAC.  In the longer term,  the MAC could trigger expres- 
sion of mRNA and synthesis of growth regulatory mole- 
cules.  This may occur either by a direct effect of the MAC 
or by an autocrine and/or paracrine action of molecules released 
during its initial interaction with the target cell membrane. 
The results of the work presented in this paper indicate that 
MAC-mediated release of growth factors from endothelium 
may be a pathogenic mechanism in proliferative disorders in 
which complement  activation and deposition of the MAC 
have been clearly established. These include atherosclerosis, 
in  both  its  classical  and  accelerated  forms,  mesangial  cell 
proliferative glomerulonephritis,  and rheumatoid  arthritis. 
Immunohistochemical methods have consistently demon- 
strated MAC complexes in atherosclerotic lesions (27), and 
the severity of cholesterol-induced atheroma is markedly re- 
duced in rabbits  deficient in C6  (28).  Plasma  and platelet 
growth factors do not fully account for the abnormal prolifer- 
ation of smooth muscle cells that characterizes  the atheroma- 
tous lesions, implying that  other factors are involved.  Our 
finding that conditioned media from MAC-treated endothelial 
cells strongly stimulates DNA synthesis in rat vascular smooth 
muscle cells (Table 2) indicates that MAC-induced release of 
bFGF and PDGF from endothelium may contribute signifi- 
cantly to the proliferative response of smooth muscle cells 
in atheromas.  Synergism between bFGF and PDGF would 
further  potentiate  their mitogenic  effect. 
Experimental  and clinical evidence indicate that comple- 
ment and growth factors are involved in the onset of mesan- 
gial cell proliferation in proliferative  glomerulonephritis (29). 
In the work reported here,  we have shown that  mitogens 
released by the MAC  from  endothelial  cells  stimulate  the 
proliferation of mesangial cells (Table 2). Floege et al.  (30) 
have recently found that antibody-sensitized mesangial cells 
lysed by complement also release active bFGF into the cul- 
ture medium. Thus, release of growth factors from endothelial 
and from mesangial cells may act synergistically to induce 
mesangial cell proliferation, expansion of the mesangial ma- 
trix and, ultimately, glomerulosclerosis. It has been recently 
reported that bFGF released by mechanical injury of cultured 
endothelial cells stimulate synovial cell proliferation (31). It 
is conceivable that  in rheumatoid  arthritis,  where comple- 
ment activation in the synovial fluid and deposition of the 
MAC in the synovial surface have been well documented (20), 
MAC-induced release of mitogens may play a major role in 
the abnormal proliferation of synovial cells that characterizes 
this condition. 
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